Form 4: Harvard Apparatus Regenerative Technology CEO Acquires Additional Shares
SEC Form 4 Filing
CEO of Harvard Apparatus Regenerative Technology, He Junli, reports the acquisition of common stock through a series of transactions.
Summary
- On August 27, 2024, He Junli, CEO of Harvard Apparatus Regenerative Technology, Inc. (HRGN), acquired 5,101 shares of common stock at a weighted average price of $3.37.
- Following this transaction, He Junli directly owns 259,701 shares of HRGN common stock.
- The purchase was executed under a 10b5-1(c) trading plan.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The CEO's purchase of shares is generally a positive sign, but the document itself is simply a regulatory filing.
Positives
- The CEO's purchase of shares may signal confidence in the company's future prospects.
Industry Context
Insider transactions are closely monitored by investors as they can provide insights into management's perspective on the company's valuation and future performance. Purchases are generally viewed more positively than sales.
Stakeholder Impact
- Shareholders may view the CEO's stock purchase as a positive signal.
Key Dates
| Date | Description |
|---|---|
| 08/27/2024 | Date of the transaction where common stock was acquired. |
| 09/12/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.